Evidence map›Paper›PMID 31931613›Full record

ArticleCirculation2020

Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts.

Shigemiki Omiya, Yosuke Omori, Manabu Taneike, Tomokazu Murakawa, Jumpei Ito, Yohei Tanada, Kazuhiko Nishida, Osamu Yamaguchi, Takashi Satoh, Ajay M Shah and 2 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Cardiomyocytes regulate Inflammation in the failing heart.American journal of physiology. Heart and circulatory physiology · 2025
    Article
  6. Review
  7. Mechanisms of mitochondrial damage-associated molecular patterns associated with inflammatory response in cardiovascular diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The trans-omics landscape of COVID-19.Nature communications · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Shigemiki OmiyaThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Yosuke OmoriThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Manabu TaneikeThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Tomokazu MurakawaThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Jumpei ItoThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Yohei TanadaThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Kazuhiko NishidaThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Osamu YamaguchiDepartment of Cardiovascular Medicine, Graduate School of Medicine (O.Y.), Osaka University, Suita, Japan.
Takashi SatohLaboratory of Host Defense, Research Institute for Microbial Diseases (T.S., S.A.), Osaka University, Suita, Japan.
Ajay M ShahThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
Shizuo AkiraLaboratory of Host Defense, Research Institute for Microbial Diseases (T.S., S.A.), Osaka University, Suita, Japan.
Kinya OtsuThe School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, United Kingdom (S.O., Y.O., M.T., T.M., J.I., Y.T., K.N., A.M.S., K.O.).
British Heart Foundation · GBThe University of Osaka · JP

Funding

British Heart Foundation CH/11/3/29051British Heart Foundation CH/1999001/11735British Heart Foundation RG/13/11/30384British Heart Foundation RG/16/15/32294
6 · The paper itself

Abstract

backgroundProinflammatory cytokines play an important role in the pathogenesis of heart failure. The mechanisms responsible for maintaining sterile inflammation within failing hearts remain poorly defined. Although transcriptional control is important for proinflammatory cytokine gene expression, the stability of mRNA also contributes to the kinetics of immune responses. Regnase-1 is an RNase involved in the degradation of a set of proinflammatory cytokine mRNAs in immune cells. The role of Regnase-1 in nonimmune cells such as cardiomyocytes remains to be elucidated.

methodsTo examine the role of proinflammatory cytokine degradation by Regnase-1 in cardiomyocytes, cardiomyocyte-specific Regnase-1-deficient mice were generated. The mice were subjected to pressure overload by means of transverse aortic constriction to induce heart failure. Cardiac remodeling was assessed by echocardiography as well as histological and molecular analyses 4 weeks after operation. Inflammatory cell infiltration was examined by immunostaining. Interleukin-6 signaling was inhibited by administration with its receptor antibody. Overexpression of Regnase-1 in the heart was performed by adeno-associated viral vector-mediated gene transfer.

resultsCardiomyocyte-specific Regnase-1-deficient mice showed no cardiac phenotypes under baseline conditions, but exhibited severe inflammation and dilated cardiomyopathy after 4 weeks of pressure overload compared with control littermates. Four weeks after transverse aortic constriction, the

conclusionsThe degradation of cytokine mRNA by Regnase-1 in cardiomyocytes plays an important role in restraining sterile inflammation in failing hearts and the Regnase-1-mediated pathway might be a therapeutic target to treat patients with heart failure.

Indexed as

InflammationInterleukin-6Myocytes, CardiacRibonucleasesRNA, MessengerAnimalsAntibodiesCardiomyopathy, DilatedGenetic VectorsHeart FailureMiceMice, Inbred C57BLMice, KnockoutReceptors, Interleukin-6Up-RegulationAntibodiesInterleukin-6Receptors, Interleukin-6RibonucleasesRNA, MessengerZc3h12a protein, mouseheart failureinflammationinterleukin-6RNA stability

Identifiers

PMID31931613
PMCPMC7034406
OpenAlexW3000409789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.